Ablynx NV - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Ablynx NV - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Ablynx NV - Product Pipeline Review - 2014', provides an overview of the Ablynx NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ablynx NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ablynx NV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ablynx NV's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Ablynx NV's pipeline products

Reasons to buy

- Evaluate Ablynx NV's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ablynx NV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ablynx NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ablynx NV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ablynx NV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ablynx NV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Ablynx NV Snapshot 6
Ablynx NV Overview 6
Key Information 6
Key Facts 6
Ablynx NV - Research and Development Overview 7
Key Therapeutic Areas 7
Ablynx NV - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Ablynx NV - Pipeline Products Glance 16
Ablynx NV - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Ablynx NV - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Ablynx NV - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Ablynx NV - Drug Profiles 21
ALX-0061 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
caplacizumab 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ozoralizumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ALX-0141 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ALX-0171 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ALX-0751 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibodies for Inflammation, Immunology and Infections 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclonal Antibodies for Oncology, Immunology and Neurology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody 1 for Inflammation and Immunology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody 1 For Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody 1 for Pulmonary Disease 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody 2 for Inflammation and Immunology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody 2 For Oncology 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibody 2 For Pulmonary Disease 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibody 3 for Inflammation and Immunology 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Monoclonal Antibody for Pulmonary Diseases 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Conjugated Monoclonal Antibodies for Cancer 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Ablynx NV - Pipeline Analysis 42
Ablynx NV - Pipeline Products by Target 42
Ablynx NV - Pipeline Products by Route of Administration 43
Ablynx NV - Pipeline Products by Molecule Type 44
Ablynx NV - Pipeline Products by Mechanism of Action 45
Ablynx NV - Recent Pipeline Updates 46
Ablynx NV - Dormant Projects 53
Ablynx NV - Discontinued Pipeline Products 54
Discontinued Pipeline Product Profiles 54
ALX-0962 54
Ablynx NV - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables
Ablynx NV, Key Information 6
Ablynx NV, Key Facts 6
Ablynx NV - Pipeline by Indication, 2014 9
Ablynx NV - Pipeline by Stage of Development, 2014 10
Ablynx NV - Monotherapy Products in Pipeline, 2014 11
Ablynx NV - Partnered Products in Pipeline, 2014 12
Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2014 13
Ablynx NV - Out-Licensed Products in Pipeline, 2014 14
Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2014 15
Ablynx NV - Phase II, 2014 16
Ablynx NV - Phase I, 2014 17
Ablynx NV - Preclinical, 2014 18
Ablynx NV - Discovery, 2014 19
Ablynx NV - Unknown, 2014 20
Ablynx NV - Pipeline by Target, 2014 42
Ablynx NV - Pipeline by Route of Administration, 2014 43
Ablynx NV - Pipeline by Molecule Type, 2014 44
Ablynx NV - Pipeline Products by Mechanism of Action, 2014 45
Ablynx NV - Recent Pipeline Updates, 2014 46
Ablynx NV - Dormant Developmental Projects,2014 53
Ablynx NV - Discontinued Pipeline Products, 2014 54
Ablynx NV, Subsidiaries 55